Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049399 · ClinicalTrials.gov registry record · NA
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
A NA study of Progressive Supranuclear Palsy, sponsored by Noscira.
- Completed
- Registry status
- NA
- Development phase
- 146
- Enrollment target
- 20
- Study locations
NCT01049399: Completed NA study of Progressive Supranuclear Palsy, sponsored by Noscira.
NCT01049399 is a NA study of Progressive Supranuclear Palsy that has completed, run by Noscira. The registered enrollment target is 146 participants, below the 444-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01049399, a NA study of Progressive Supranuclear Palsy, has completed, sponsored by Noscira.
- COMPLETED
- Registry status
- NA
- Development phase
- 146 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
Conditions Studied
Interventions
- DRUG placebo
- DRUG tideglusib
Study Locations (20)
Other
- Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson Beelitz - Beelitz-Heilstätten
- Humboldt Universitat Charite, Campus Virchow, Neurologisch - Berlin
- Universitatsklinikum Carl-Guslav-Carus, Technische Universitat Dresden, Klinik und Poliklinik fur Neurologie - Dresden
- Medizinische Hochschule Hannover, Neurologie 0E 7210 - Hanover
- Zentrum fur Nervenheilkunde. Klinik fur Neurologie mit Poliklinik. - Marburg
- University Hospital Tuebingen,Eberhard-Karls-Universitat, Universitatsklinikum Neurologie - Tübingen
- Hospital de Cruces - Barakaldo
- Dpto.neurologia. H. Clinic. - Barcelona
- Hospital de Donostia - Donostia / San Sebastian
- Dpt. Neurologia. Hospital Ramón y Cajal. - Madrid
- Hospital U. La Paz - Madrid
- Hospital Mutua Terrassa - Terrassa
California
- The Parkinson's and Movement Disorder Institute - Fountain Valley
- Department of Neurology, David Geffen School of Medicine at UCLA - Los Angeles
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University of South Florida 5 - Tampa
Kentucky
- Division of Movement Disorders, University of Louisville - Louisville
New Jersey
- University of Medicine and Dentistry, Robert Wood Johnson Medical School - New Brunswick
Barcelona
- Fundació Ace - Barcelona
Madrid
- Hospital Puerta del Hierro - Madrid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-11 |
| Phase | NA |
What the finished NCT01049399 record still lists
NCT01049399 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 444-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01049399 names 20 study sites across 7 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01049399 about?
NCT01049399 is a clinical study titled "Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy". The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
What is the current status of trial NCT01049399?
This trial is currently completed. It is a NA study. The enrollment target is 146 participants. The study started on 2009-12. Estimated completion is 2011-11.
What conditions does trial NCT01049399 study?
This clinical trial studies the following conditions: Progressive Supranuclear Palsy.
What interventions are being tested in trial NCT01049399?
The interventions under investigation include: placebo (DRUG), tideglusib (DRUG).
Who is sponsoring clinical trial NCT01049399?
This trial is sponsored by Noscira, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01049399 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, New Jersey, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Supranuclear Palsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01049399's enrollment target sits among peer trials
146 10th of 18 higher than 9 of 18 other Progressive Supranuclear Palsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Progressive Supranuclear Palsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
RECRUITING · NA
-
Art Therapy in Progressive Supranuclear Palsy
ACTIVE NOT RECRUITING · NA
-
Community Outreach for Palliative Engagement -- Parkinson Disease
ACTIVE NOT RECRUITING · NA
-
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)
ACTIVE NOT RECRUITING · NA
-
In-Home Care for Patients With PSP and Related Disorders
COMPLETED · NA
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia